OncoSec Medical Inc (ONCSQ)

[chickpea598]

The point of the T-Cell Exhaustion Marker data is that Oncosec can accurately choose people who will not respond to Pembrolizumab monotherapy and enroll them in the combo trial. This is the large population of cancer patients we are going after not just the people who respond to pd-1 monotherapy. This is a very risky trial but the rewards will be huge if Oncosec can turn non-responders into responders. This is a small trial so the accuracy and detail of every aspect of the data is extremely important. Knowing 100% that all patients enrolled in the combo study are non-responders is very important.